Obesity Drug Market Faces Uncertainty as Prices Fall and Competition Increases

Shifting Market Expectations

• 🎯 Wall Street's long-held expectation of a $150 billion global obesity drug market within the next decade is now facing uncertainty.
• 📉 This shift is driven by falling US prices for GLP-1 treatments from major players like Novo Nordisk and Eli Lilly, alongside increasing competition.

Recalculation of Market Peaks

• 📊 Analysts and investors are recalculating the peak market size and timing due to a rapidly changing landscape.
• ⚠️ New drug entries and pricing pressures in the consumer market are contributing factors to this reassessment.
• 💰 Some forecasts suggest the peak market size has been reduced, with the $150 billion target potentially shifting to 2035.

Key Players and Drug Performance

• 💊 Novo Nordisk and Eli Lilly, dominant players in the market, are reporting financial results amidst these changes.
• 📈 Novo's Wegovy injection and pill, along with Lilly's Zepbound injection, saw a combined total of 730,000 prescriptions in a recent week.
• 🚀 Wegovy prescriptions grew 4%, partly due to its new pill form, while Zepbound saw a 0.9% increase.